Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

a Combination of Ex Vivo and Computational Models Predicts Clinical Response in MM Treatment Combinations of Proteasome Inhibitors, Imids, Nuclear Export Inhibitors and Alkylating Agents

Ariosto Silva, PhD, Maria Silva, M.Sc, Timothy Jacobson, B.S., Mark B Meads, PhD, Allison Distler, B.S., Aunshka Collins, BS, Chris Cubitt, PhD, Lia E Perez, MD, Rachid Baz, MD, Dmitri Rebatchouk, PhD, Robert Gatenby, MD, PhD, Kenneth H. Shain, MD PhD

Blood (2016) 128 (22): 3291.

https://doi.org/10.1182/blood.V128.22.3291.3291

Published: 2016

Journal Articles

Phase II Study of a Novel Reduced Toxicity Preparative Regimen for Hematopoietic Cell Allografting Combining Pentostatin (Nipent) and Targeted Doses of Intravenous Busulfan (Busulfex) with or without Rituximab (PB±R) Using a Novel Principle of CD4-Guided Immune Suppression

Mohamed A Kharfan-Dabaja, MD, Claudio Anasetti, MD, Nathalie Luis, B.S., Linda Brand, R.N., Janelle Perkins, PharmD, Hugo F. Fernandez, MD, Jose Leonel Ochoa-Bayona, M.D., Taiga Nishihori, MD, Lia E Perez, MD, Ernesto Ayala, MD, Javier Pinilla-Ibarz, MD, PhD, Lubomir Sokol, MD, PhD, Joseph Pidala, MD, MS, Frederick L Locke, MD, Eduardo M. Sotomayor, Teresa Field, MD, PhD, Marcie Tomblyn, MD, MS

Blood (2011) 118 (21): 3022.

https://doi.org/10.1182/blood.V118.21.3022.3022

Published: 2011

Journal Articles

Presence of DRB1*01 Allele in Multiple Myeloma Patients Is Associated with Indolent Disease.

M. Alcoceba, L. Marin, A. Balanzategui, M.E. Sarasquete, PhD, P. Martin-Jimenez, PhD, M.C. Chillon, PhD, M. Vargas, R. Corral, MD, E. Perez, MD, J. Fernandez-Calvo, MD, PhD, A. Martinez, MD, PhD, J.M. Hernandez, MD, PhD, Joan Blade, MD, PhD, J.J. Lahuerta, MD, PhD, R. Garcia-Sanz, MD, PhD, M. Gonzalez, MD, PhD, J.F. San Miguel, MD, PhD

Blood (2007) 110 (11): 1481.

https://doi.org/10.1182/blood.V110.11.1481.1481

Published: 2007

Journal Articles

Environmental Mediated-Immune Resistance (EM-IR) to APO2L/TRAIL Mediated Apoptosis.

Lia E. Perez, MD, Nancy Parquet, BS, Marina Molisano, BS, Ken Shain, Ph.D, Melisa Alsina, MD, Claudio Anasetti, MD, William Dalton, Ph.D. MD

Blood (2007) 110 (11): 3521.

https://doi.org/10.1182/blood.V110.11.3521.3521

Published: 2007

Journal Articles

Microenvironment Confers Resistance to TRAIL Mediated Apoptosis.

Lia E. Perez, MD, Nancy Parquet, BS, Ramadevi Nimmanapalli, DVM, PhD, Melissa Alsina, M.D, Claudio Anasetti, MD, William Dalton, PhD MD

Blood (2005) 106 (11): 2489.

https://doi.org/10.1182/blood.V106.11.2489.2489

Published: 2005

NARROW

a Combination of Ex Vivo and Computational Models Predicts Clinical Response in MM Treatment Combinations of Proteasome Inhibitors, Imids, Nuclear Export Inhibitors and Alkylating Agents

Phase II Study of a Novel Reduced Toxicity Preparative Regimen for Hematopoietic Cell Allografting Combining Pentostatin (Nipent) and Targeted Doses of Intravenous Busulfan (Busulfex) with or without Rituximab (PB±R) Using a Novel Principle of CD4-Guided Immune Suppression

Presence of DRB1*01 Allele in Multiple Myeloma Patients Is Associated with Indolent Disease.

Environmental Mediated-Immune Resistance (EM-IR) to APO2L/TRAIL Mediated Apoptosis.

Microenvironment Confers Resistance to TRAIL Mediated Apoptosis.

Email alerts

ASH Publications

American Society of Hematology

a Combination of Ex Vivo and Computational Models Predicts Clinical Response in MM Treatment Combinations of Proteasome Inhibitors, Imids, Nuclear Export Inhibitors and Alkylating Agents

Phase II Study of a Novel Reduced Toxicity Preparative Regimen for Hematopoietic Cell Allografting Combining Pentostatin (Nipent) and Targeted Doses of Intravenous Busulfan (Busulfex) with or without Rituximab (PB±R) Using a Novel Principle of CD4-Guided Immune Suppression

Presence of DRB1*01 Allele in Multiple Myeloma Patients Is Associated with Indolent Disease.

Environmental Mediated-Immune Resistance (EM-IR) to APO2L/TRAIL Mediated Apoptosis.

Microenvironment Confers Resistance to TRAIL Mediated Apoptosis.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only